Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2,896 Mln
P/E Ratio
--
P/B Ratio
4.47
Industry P/E
--
Debt to Equity
0
ROE
-0.43 %
ROCE
--
Div. Yield
0 %
Book Value
9.41
EPS
-3.24
CFO
$-655.87 Mln
EBITDA
$-729.92 Mln
Net Profit
$-705.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Merus N.V. - ADR
| 2.39 | -8.59 | 8.59 | 6.81 | 18.07 | 28.33 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Merus N.V. - ADR
| 77.76 | -51.35 | 81.40 | 24.50 | 0.57 | -27.71 | -8.10 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 14.00 | 747.65 | -- | -49.94 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or... non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Address: Uppsalalaan 17, Utrecht, Netherlands, 3584 CT Read more
CEO, President & Executive Director
Dr. Sven Ante Lundberg M.D.
CEO, President & Executive Director
Dr. Sven Ante Lundberg M.D.
Headquarters
Utrecht
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Merus NV - ADR stood at $ 1,352 Mln as on 31-Mar-25
The share price of Merus NV - ADR is $43.06 (NASDAQ) as of 17-Apr-2025 16:15 EDT. Merus NV - ADR has given a return of 18.07% in the last 3 years.
Merus NV - ADR has a market capitalisation of $ 2,896 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Merus NV - ADR is 4.47 times as on 17-Apr-2025, a 79% premium to its peers’ median range of 2.50 times.
Since, TTM earnings of Merus NV - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Merus NV - ADR and enter the required number of quantities and click on buy to purchase the shares of Merus NV - ADR.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Address: Uppsalalaan 17, Utrecht, Netherlands, 3584 CT
The CEO & director of Dr. Sven Ante Lundberg M.D.. is Merus NV - ADR, and CFO & Sr. VP is Dr. Sven Ante Lundberg M.D..
There is no promoter pledging in Merus NV - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
105
|
| Merus N.V. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-31.35
|
|
Operating margin(%)
|
-887.8
|
|
Net Margin(%)
|
-566.53
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Merus NV - ADR was $0 Mln.
$1.15
(
